Navigation Links
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Date:7/9/2008

ieved to have superior anticoagulant effects compared to other targets such as thrombin. Portola believes betrixaban will offer several advantages over warfarin and the FXa inhibitors in development, including a long half-life to support once-daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment.

Portola has successfully completed a Phase 2 trial demonstrating betrixaban's proof of clinical concept and a favorable tolerability profile in preventing venous thromboembolism in patients undergoing knee replacement surgery. Later this year, Portola will initiate a Phase 2 clinical study in 500 patients comparing the safety and tolerability of betrixaban to warfarin, the only marketed chronic, oral anticoagulant for stroke prevention in patients with atrial fibrillation.

The other Phase 2 drug candidate is PRT060128, an antiplatelet agent that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit over clopidogrel and other antiplatelet agents in development through its immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola's clinical studies to date with the IV and oral formulations have shown that PRT060128 is well tolerated at high drug levels. Later this year, Portola will initiate a Phase 2 trial comparing the safety, tolerability and efficacy of the IV bolus followed by the oral formulation (60 days of therapy) of PRT060128 to clopidogrel in 800 patients undergoing elective percutaneous coronary interventions (PCI).

Expanding Early Stage Pipeline

Portola is developing a universal Factor Xa inhibitor antidote with the goal of neutralizing the effect of small molecule Factor Xa inhibitors in patients experiencing moderate or major ble
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Completes Bio-Distribution Studies
2. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
10. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
11. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BOSTON , September 16, 2014 ... Fiona Marshall , will give a presentation entitled " ... StaR ®   technology " ... and Development " virtual symposium run by Chemical & Engineering ... symposium is on Wednesday, 24 September 2014; Dr Marshall,s presentation ...
(Date:9/15/2014)... FRANCISCO , Sept. 15, 2014 ... studies presented at the American Society for Radiation ... its Decipher® Prostate Cancer Classifier, a genomic test ... influence treatment decisions and improve patient outcomes for ... These presentations follow a recently published study that ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data on the ... report provides value, in millions of US dollars, ... dollars) within market segments Invasive Body Contouring Devices ... Radio Frequency-Assisted Liposuction (RFAL) Devices, Ultrasound-Assisted Liposuction (UAL) ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5
... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... emerging leader in the development, assembly, marketing and sale ... today announced that it was granted three new patents ... of China ("SIPO"). The patent awards were related to ...
... Cellular Dynamics International (CDI) today announced the online publication ... demonstrating for the first time a methodology for researchers ... blood samples through the creation of induced pluripotent stem ... B-cell lines reprogrammed to EBV-free induced pluripotent stem cells," ...
Cached Medicine Technology:Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2
(Date:9/16/2014)... Discussion abstracts to be presented at the ESMO 2014 ... 2014 at 12:00 (CEST) to give you a first ... medical oncology Congress, under the leading theme Precision Medicine ... where genuinely targeted therapy is now possible for an ... are all working towards a common goal --improved patient ...
(Date:9/16/2014)... Perkins, OK (PRWEB) September 16, 2014 ... Superfood, rich in iron and potassium. They are ... high nutritional values and their healing and health ... and meaty texture Shiitakes can stimulate and strengthen ... infections. Shiitakes contain polycharrides, including beta ...
(Date:9/16/2014)... Atlanta, GA (PRWEB) September 16, 2014 ... cloud-based clinical, business management and billing software solutions ... immediate availability of its latest release of ... providers, orthotics and prosthetics providers as well as ... for prior authorization requests (PARs), electronic purchasing, document ...
(Date:9/16/2014)... Albany, New York (PRWEB) September 16, 2014 ... intelligence firm states that the global facial care market ... billion by 2019. The report, titled ‘Facial Care Market ... Facial Creams, Face Wash, Cleansing Wipes, Serums and Masks ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 ...
(Date:9/16/2014)... Cloud based mobile app builder Appy ... API’S to serve m3u8 streams on Android & iOS. ... video events with hundreds of thousands of simultaneous viewers ... is known for making beautiful and interactive apps for ... 8 and already over 100,000 apps have passed through ...
Breaking Medicine News(10 mins):Health News:ESMO 2014 Congress Preview 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3Health News:Brightree Announces Availability of Latest Release 2Health News:Brightree Announces Availability of Latest Release 3Health News:Brightree Announces Availability of Latest Release 4Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... their seatbelts than the rest of the population, adding ... growing problem. , The connection was made by ... Meharry Medical College in Nashville, Tenn. , We found ... Schlundt, associate professor of psychology and assistant professor of ...
... as a non-invasive way to determine the existence and ... development of pharmacologic strategies to combat the condition. These ... journal published by John Wiley & Sons on behalf ... Diseases (AASLD). The article is also available online at ...
... two editorials published in the September 2007 issue ... medical ethicist discussed whether doctors should participate in ... discussions about physician involvement in capital punishment have ... court systems. And the North Carolina Medical Board ...
... Commissioner Dr. Thomas R. Frieden, and Consumer Affairs Commissioner Jonathan ... City Youth Risk Behavior Survey (YRBS) showing that cigarette smoking ... 2005 and 2007. The citys teen smoking rate has dropped ... 17.6 percent in 2001 to 8.5 percent in 2007. The ...
... BOSTON, Mass. (Jan. 2, 2008) Athanasios Zavras began ... reports linked oral osteoporosis meds to bone death in ... women and men taking these drugs to postpone dental ... exacerbate the problem. Thats when Zavras, an associate professor ...
... misguided zealots are promoting numerous stress reduction devices, ... The vast majority are supported only by ... others. Very often, as in the case ... stress, scholarly articles from prestigious journals are cited ...
Cached Medicine News:Health News:Obesity linked to decreased seatbelt use 2Health News:MRI techniques evolving towards better assessment of liver fibrosis 2Health News:Mayo Clinic Proceedings provides forum for debate about capital punishment 2Health News:Mayo Clinic Proceedings provides forum for debate about capital punishment 3Health News:Smoking rate among New York City teens was lowest on record in 2007 2Health News:Smoking rate among New York City teens was lowest on record in 2007 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: